Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)

BALA CYNWYD, Pa., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

NUVASIVE (Nasdaq – NUVA)

Under the terms of the deal, NUVASIVE will be acquired by Globus Medical. NUVASIVE shareholders will receive 0.75 of a share of Globus Medical Class A common stock for each share of NUVASIVE common stock owned at the closing of the transaction. Based on this exchange ratio, the implied share price for NUVASIVE would be $57.72, an equity value of $3.1 billion, based on Globus Medical's closing share price on February 8. Following the close of the transaction, NUVASIVE shareholders will own approximately 28% of the combined company, and Globus Medical shareholders will own approximately 72%, on a fully diluted basis. The investigation concerns whether the NUVASIVE Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Globus Medical is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/nuvasive-nasdaq-nuva/.

Oak Street Health (NYSE – OSH)

Under the terms of the Merger Agreement, Oak Street Health be acquired by CVS Health® (“CVS”) (NYSE - CVS). Oak Street Health stockholders will receive $39.00 per share in an all-cash transaction, representing an enterprise value of approximately $10.6 billion. The investigation concerns whether the Oak Street Health Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether CVS is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/oak-street-health-nyse-osh/.

Argo Group International Holdings, Ltd. (NYSE - ARGO)

Under the terms of the Merger Agreement, Argo will be acquired by Brookfield Reinsurance (“Brookfield”) (NYSE - BNRE). Argo stockholders will receive $30.00 per common share in a deal valued at approximately $1.1 billion. The investigation concerns whether the Argo Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Brookfield is paying too little for the Company. For example, the deal price is below the 52-week high of $45.26 for the Company’s shares.

Additional information can be found at https://www.brodskysmith.com/cases/argo-group-international-holdings-ltd-nyse-argo/.

Cardiovascular Systems, Inc. (Nasdaq – CSII)

Under the terms of the agreement, Cardiovascular Systems will be acquired by Abbott (NYSE - ABT). Cardiovascular Systems stockholders will receive $20 per common share at a total expected equity value of approximately $890 million. The investigation concerns whether the Cardiovascular Systems Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Abbott is paying too little for the Company. For example, the deal price is below the 52-week high of $23.47 for the Company’s shares.

Additional information can be found at https://www.brodskysmith.com/cases/cardiovascular-systems-inc-nasdaq-csii/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.